Lung cell therapy shows promise in IPF trial
NCT ID NCT06081621
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new cell therapy called REGEND001 for people with idiopathic pulmonary fibrosis (IPF), a serious lung disease. The therapy uses special lung cells to try to repair damaged tissue. In this phase 2 trial, 23 participants received either the cell therapy or a placebo to see if it could improve lung function over 24 weeks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
-
Renji Hospital, Shanghai Jiaotong University School Of Medicine
Shanghai, Shanghai Municipality, 200127, China
-
Ruijin Hospital, Shanghai Jiaotong University School Of Medicine
Shanghai, Shanghai Municipality, 200025, China
-
The Second Affiliated Hospital of Xiamen Medical College
Xiamen, Fujian, 361021, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill slow lung scarring in IPF?
- Beyond the lungs: the hidden emotional toll of IPF medications
- Can umbilical cord stem cells ease a scarring lung disease?
- Spotting hidden blood clots in scarred lungs: a study hunts for clues
- What makes someone stop a lung fibrosis drug? a study asks patients directly
- A smarter way to track lung disease? new platform aims to personalize COPD and IPF care